High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study

Introduction: Third-generation EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes in EGFR-mutant non–small cell lung cancer (NSCLC), but resistance occurs, especially in patients with Brain metastases (BMs). Antiangiogenic therapy may enhance CNS drug delivery and EGFR-TKI efficacy​. We e...

Full description

Saved in:
Bibliographic Details
Main Authors: Yin Pan, Meichen Li, Mingjie Yu, Jing Chen, Hui Yu, Kaijing Liu, Likun Chen
Format: Article
Language:English
Published: Elsevier 2025-11-01
Series:Translational Oncology
Subjects:
Furmonertinib
EGFR-TKI resistance
Brain Metastases
EGFR mutation
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523325002311
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items